Total Payments
$9,409
2024 Payments
$264.10
Companies
34
Transactions
217
Medicare Patients
4,284
Medicare Billing
$533,339
Payment Breakdown by Category
Food & Beverage$7,460 (79.3%)
Travel$1,509 (16.0%)
Education$440.12 (4.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,460 | 210 | 79.3% |
| Travel and Lodging | $1,509 | 3 | 16.0% |
| Education | $440.12 | 4 | 4.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $2,140 | 7 | $0 (2024) |
| Abbott Laboratories | $1,573 | 22 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $701.15 | 35 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $582.97 | 28 | $0 (2024) |
| Medtronic Vascular, Inc. | $529.15 | 8 | $0 (2019) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $433.39 | 25 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $365.13 | 4 | $0 (2019) |
| United Therapeutics Corporation | $333.84 | 3 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $332.72 | 6 | $0 (2022) |
| Amgen Inc. | $319.39 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $264.10 | 14 | Esperion Therapeutics, Inc. ($47.04) |
| 2023 | $151.99 | 8 | Novo Nordisk Inc ($40.26) |
| 2022 | $436.05 | 12 | Actelion Pharmaceuticals US, Inc. ($125.00) |
| 2021 | $319.13 | 6 | United Therapeutics Corporation ($248.15) |
| 2020 | $238.71 | 6 | Abbott Laboratories ($155.05) |
| 2019 | $989.04 | 29 | Janssen Pharmaceuticals, Inc ($154.55) |
| 2018 | $3,462 | 81 | Abbott Laboratories ($851.15) |
| 2017 | $3,548 | 61 | BOSTON SCIENTIFIC CORPORATION ($1,706) |
All Payment Transactions
217 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Genetic Disease | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.83 | General |
| Category: Cardiovascular | ||||||
| 11/05/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Cardiology | ||||||
| 11/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: Cardiology | ||||||
| 10/28/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/12/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $3.32 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 06/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Cardiology | ||||||
| 04/04/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $30.78 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 03/25/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 03/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.20 | General |
| 03/18/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/20/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 01/18/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Cardiology | ||||||
| 12/20/2023 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Cardiology | ||||||
| 12/06/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.93 | General |
| Category: Cardiovascular | ||||||
| 10/04/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Diabetes | ||||||
| 09/13/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Cardiology | ||||||
| 08/24/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: DIABETES | ||||||
| 07/14/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Diabetes | ||||||
| 07/07/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/17/2023 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $24.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/01/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Cardiology | ||||||
| 11/02/2022 | United Therapeutics Corporation | ORENITRAM (Drug) | Food and Beverage | In-kind items and services | $85.69 | General |
| Category: PAH | ||||||
| 10/28/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $10.25 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 666 | 1,247 | $306,624 | $73,905 |
| 2022 | 18 | 738 | 1,275 | $373,677 | $92,895 |
| 2021 | 11 | 484 | 791 | $209,777 | $56,975 |
| 2020 | 22 | 2,396 | 3,291 | $990,083 | $309,564 |
Total Patients
4,284
Total Services
6,604
Medicare Billing
$533,339
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 131 | 218 | $78,623 | $19,167 | 24.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 82 | 83 | $45,771 | $10,838 | 23.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 24 | 24 | $29,419 | $7,779 | 26.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 24 | 93 | $25,575 | $4,242 | 16.6% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 22 | 146 | $16,300 | $4,142 | 25.4% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 22 | 44 | $15,276 | $3,992 | 26.1% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 23 | 112 | $15,303 | $3,860 | 25.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 23 | 112 | $15,374 | $3,822 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $15,102 | $3,561 | 23.6% |
| 99424 | Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | Office | 2023 | 19 | 45 | $10,486 | $2,334 | 22.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 144 | 204 | $8,269 | $1,991 | 24.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 30 | $6,734 | $1,804 | 26.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $6,399 | $1,714 | 26.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 27 | 27 | $5,365 | $1,424 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 19 | $4,858 | $1,157 | 23.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 20 | 21 | $4,087 | $1,095 | 26.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 11 | 12 | $3,058 | $816.36 | 26.7% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 12 | 12 | $624.60 | $167.28 | 26.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 141 | 142 | $82,052 | $19,759 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 211 | $78,973 | $19,386 | 24.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 24 | 24 | $31,280 | $8,324 | 26.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 53 | 53 | $25,906 | $6,081 | 23.5% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 24 | 93 | $17,462 | $4,496 | 25.7% |
| 99424 | Principal care management services for a single high-risk disease, first 30 minutes provided personally by qualified health care professional, per calendar month. | Office | 2022 | 13 | 67 | $16,763 | $4,064 | 24.2% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 21 | 41 | $13,760 | $3,793 | 27.6% |
About Dr. Sunit Tolia, DO
Dr. Sunit Tolia, DO is a Nuclear Cardiology healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/29/2013. The National Provider Identifier (NPI) number assigned to this provider is 1427493865.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sunit Tolia, DO has received a total of $9,409 in payments from pharmaceutical and medical device companies, with $264.10 received in 2024. These payments were reported across 217 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($7,460).
As a Medicare-enrolled provider, Tolia has provided services to 4,284 Medicare beneficiaries, totaling 6,604 services with total Medicare billing of $533,339. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Cardiology
- Other Specialties Cardiovascular Disease
- Location Greensboro, NC
- Active Since 04/29/2013
- Last Updated 10/03/2024
- Taxonomy Code 207UN0901X
- Entity Type Individual
- NPI Number 1427493865
Products in Payments
- WATCHMAN (Device) $2,110
- XARELTO (Drug) $701.15
- CardioMEMS HF System (Device) $671.50
- ENTRESTO (Drug) $538.41
- LifeVest (Device) $433.39
- PRALUENT ALIROCUMAB INJECTION (Biological) $347.67
- IN.PACT Admiral (Device) $338.41
- Adempas (Drug) $294.26
- ELIQUIS (Drug) $289.01
- Accent Pacemaker (Device) $282.32
- PRALUENT (Drug) $237.21
- EKOSONIC (Device) $210.91
- ORENITRAM (Drug) $208.84
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $193.80
- Repatha (Biological) $176.05
- Ensite Cardiac Mapping System (Device) $152.81
- JARDIANCE (Drug) $139.56
- Barostim Neo System (Device) $136.11
- Supera peripheral stent system (Device) $125.00
- UPTRAVI (Drug) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.